3 Day Course: Runs from Monday midday to Thursday midday - 11th - 14th March 2019.
Clinical trials in therapeutic areas such as cardiovascular disease, cancer and stroke are major undertakings. Many turn out to be negative and do not lead to the registration of a new drug or the introduction of a new treatment. Consequently, there is growing interest amongst clinical researchers in the use of efficient methods for conducting early phase trials to identify the most promising compounds for further study, and in using interim analyses to allow trials to be stopped as soon as there is sufficient evidence to reach a convincing conclusion.
Adaptive designs also allow mid-trial modifications to be made to the design so that the accumulating data guides investigators to the most appropriate form of evaluation. Bayesian methods facilitate the inclusion of prior information drawn from expert opinion and from historical data in the planning and interpretation of clinical trials, which can lead to more efficient drug development.
Evaluation of adaptive designs and Bayesian methods using SAS will be demonstrated and used in practicals. Discussion groups will focus on dilemmas involved in implementation.
Important please note:
We will make every attempt to accommodate Lancaster University staff and postgraduate research students on our courses. However, if a course becomes fully booked we reserve the right to give priority to students on the MSc in Statistics, MSc in Data Science, and external participants.
Details of course fees.
Payment: Once you have registered, please pay at the online shop
Accommodation Details: Can be found here.
Registrations are transferable to another course or individual at any time. Full refunds will be given for cancellation 10 or more working days before the course start date. Otherwise the full course fee will be charged.
Single-stage and two-stage designs
Group sequential designs and their evaluation
Sample size reviews
Response adaptive designs
A review of the Bayesian approach
Bayesian methods for phase II and phase III clinical trials
Bayesian versus frequentist approaches